公式動画ピックアップ
AAPL
ADBE
ADSK
AIG
AMGN
AMZN
BABA
BAC
BL
BOX
C
CHGG
CLDR
COKE
COUP
CRM
CROX
DDOG
DELL
DIS
DOCU
DOMO
ESTC
F
FIVN
GILD
GRUB
GS
GSK
H
HD
HON
HPE
HSBC
IBM
INST
INTC
INTU
IRBT
JCOM
JNJ
JPM
LLY
LMT
M
MA
MCD
MDB
MGM
MMM
MSFT
MSI
NCR
NEM
NEWR
NFLX
NKE
NOW
NTNX
NVDA
NYT
OKTA
ORCL
PD
PG
PLAN
PS
RHT
RNG
SAP
SBUX
SHOP
SMAR
SPLK
SQ
TDOC
TEAM
TSLA
TWOU
TWTR
TXN
UA
UAL
UL
UTX
V
VEEV
VZ
WDAY
WFC
WK
WMT
WORK
YELP
ZEN
ZM
ZS
ZUO
公式動画＆関連する動画 [Episode 5: Interpretation of CDx markers - How do we ensure proper training?]
In the fifth episode of Agilent’s “Dialogues in CDx” podcast, we discuss how to ensure proper training for PD-L1 interpretation. Two leaders who are shaping this space discuss why training is important, the best practices, and how it impacts patient care.
The first guest in this episode is Dr. Bharat Jasani, Emeritus Professor in Cancer Pathology in the School of Medicine at Cardiff University. Dr. Jasani has been extensively involved in training of more than 1,000 pathologists worldwide in quality assurance and scoring, as well as interpretation of cancer biomarker expression, particularly PD-L1 and HER2.
Also joining the conversation is Karin Salomon who has worked for Agilent Technologies in R&D for more than 20 years as a principal microscopy expert. Karin is evaluating thousands of HER2 and PD-L1 stained slides every year and trains pathologists in scoring of various biomarkers through Agilent’s Biomarker Pathologist Training Program in Europe.
This podcast series is part of the educational resources supporting the PD-L1 IHC 22C3 pharmDx assay.
For access to all episodes plus a wealth of additional PD-L1 education for pathologists, explore Agilent’s CDx Digital Education Portal today: https://bit.ly/3EETZ9t
The “Dialogues in CDx” podcast can also be found on Spotify and on Apple Podcasts.
D0133059 _1.00
87
0